Zosuquidar (LY335979) is a widely used experimental P-glycoprotein (P-gp) inhibitor, which is commended as very potent but also as very specific for P-gp. In this in vitro and in silico study, we demonstrated for the first time that zosuquidar also inhibits organic cation transporters (OCT) 1-3, albeit less potently than P-gp. This still has to be kept in mind when zosuquidar is used to inhibit cellular efflux of P-gp substrates that are concurrently transported into the cells by OCTs. To avoid interference in these assays, zosuquidar concentrations should be kept below 1 μM.
- MeSH
- Quinolines * pharmacology MeSH
- Dibenzocycloheptenes MeSH
- HEK293 Cells MeSH
- Humans MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 * antagonists & inhibitors MeSH
- Organic Cation Transport Proteins * antagonists & inhibitors metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Modulation of the cardiac autonomic nervous system (ANS) is a promising adjuvant therapy in the treatment of atrial fibrillation (AF). In pre-clinical models, pulsed field (PF) energy has the advantage of selectively ablating the epicardial ganglionated plexi (GP) that govern the ANS. This study aims to demonstrate the feasibility and safety of epicardial ablation of the GPs with PF during cardiac surgery with a primary efficacy outcome of prolongation of the atrial effective refractory period (AERP). METHODS: In a single-arm, prospective analysis, patients with or without a history of AF underwent epicardial GP ablation with PF during coronary artery bypass grafting (CABG). AERP was determined immediately pre- and post- GP ablation to assess cardiac ANS function. Holter monitors were performed to determine rhythm status and heart rate variability (HRV) at baseline and at 1-month post-procedure. RESULTS: Of 24 patients, 23 (96%) received the full ablation protocol. No device-related adverse effects were noted. GP ablation resulted in a 20.7 ± 19.9% extension in AERP (P < 0.001). Post-operative AF was observed in 7 (29%) patients. Holter monitoring demonstrated an increase in mean heart rate (74.0 ± 8.7 vs. 80.6 ± 12.3, P = 0.01). There were no significant changes in HRV. There were no study-related complications. CONCLUSIONS: This study demonstrates the safety and feasibility of epicardial ablation of the GP using PF to modulate the ANS during cardiac surgery. Large, randomized analyses are necessary to determine whether epicardial PF ablation can offer a meaningful impact on the cardiac ANS and reduce AF. TRIAL REGISTRATION: Clinical trial registration: NCT04775264.
- MeSH
- Electrocardiography, Ambulatory MeSH
- Electroporation * methods MeSH
- Atrial Fibrillation * surgery MeSH
- Ganglia, Autonomic * surgery MeSH
- Catheter Ablation * methods MeSH
- Coronary Artery Bypass * methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Pericardium * surgery innervation MeSH
- Prospective Studies MeSH
- Aged MeSH
- Feasibility Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Study MeSH
Východisko: Společnost všeobecného lékařství ČLS JEP periodicky monitoruje názory občanů na vybrané aspekty problematiky zdravotnictví a zdravého způsobu života. Tato publikace navazuje na předchozí výstupy průzkumů provedených v letech 2015 až 2024. Cíl a metody: Cílem výzkumu bylo zjistit, jaké jsou názory občanů na vybrané součásti práce všeobecných praktických lékařů (VPL) a na zdravotní systém a jejich úlohu v něm. K provedení reprezentativního sociologického výzkumu názorů občanů byla v ČR zvolena metoda řízeného rozhovoru tazatele s respondentem (face-to-face), realizovaná profesionální agenturou. Statistické zpracování dat bylo provedeno programem SASD 1.5.8 (Statistická analýza sociálních dat). Závěry výzkumu jsou reprezentativní pro občany ČR z hlediska jejich pohlaví, věku a regionu. Výsledky: Občané ČR jsou ve většině případů s péčí a časem, který jim věnuje v průběhu jejich návštěvy praktický lékař, spokojeni, negativní stanovisko zaujímá jen malá část (6,8 %) z nich. Největší spokojenost s péčí praktického lékaře a časem, který jim věnuje, se vrátila na úroveň let 2018–2020, tj. na úroveň před pandemií covid-19. Lze rovněž konstatovat, že občané ČR jsou s prací zdravotní sestry v ordinaci jejich praktického lékaře spokojeni, negativní stanovisko zaujímá též jen malá část (5,4 %) z nich. Občané vnímají týmové praxe pozitivně, i když (56,9 %) preferuje, aby je vždy ošetřoval jen „jejich“ praktický lékař, což lze zabezpečit v rámci objednávkového systému. V oblasti preventivní péče jsou stále v ČR významné rezervy a jen cca 50 % občanů na ní aktivně participuje. Silnou se ukazuje do budoucna kombinace aktivit VPL a vlastní motivace občanů na zlepšení zdraví. Prevenci jako významnou ke zlepšení svého zdraví hodnotí 80 % respondentů a 75,4 % respondentů by respektovalo rady na změnu životního stylu od VPL nebo lékaře specialisty v rámci preventivní péče. Jen necelá 1/3 (30,8 %) občanů míní, že zdravým životním stylem žije, téměř ½ (48,0 %) občanů se domnívá, že zdravým životním stylem žije občas. Občané se domnívají, že největším rizikem, které je ohrožuje, je nedostatek pohybu (27,0 %), dalších 23,7 % respondentů označilo jako největší riziko špatné stravování, 20,0 % občanů považuje za největší riziko stres na pracovišti a 19,8 % nedostatek spánku. Nejmenším rizikem je dle mínění dotázaných stres doma (označilo 9,5 % respondentů). Výsledky budou využity v rámci připravovaných plánovaných změn v preventivní péči u VPL v ČR.
Býma S, Javorská K, Halata D, Borský P. Citizens’ opinions on some aspects of the activities of general practitioners 2024 Background: The Czech Society of General Practitioners (CSPG) periodically monitors citizens’ opinions on selected aspects of healthcare and healthy lifestyle issues. This publication follows up on previous results of surveys conducted in 2015–2024. Aim and methods: The aim of the research was to find out what citizens’ opinions are on selected parts of the work of general practitioners (GPs) and on the healthcare system and their role in it. To conduct a representative sociological survey of citizens’ opinions in the Czech Republic, the method of controlled interview between the interviewer and the respondent (face-to-face), implemented by a professional agency, was chosen. Statistical data processing was performed using the SASD 1.5.8 program (Statistical Analysis of Social Data). The conclusions of the research are representative of citizens of the Czech Republic in terms of their gender, age and region. Results: Citizens of the Czech Republic are in most cases satisfied with the care and time that a general practitioner devotes to them during their visit, and only a small part (6.8%) of them have a negative opinion. The highest satisfaction with the care of a general practitioner and the time they devote to them has returned to the level of 2018–2020, i.e. to the level before the covid-19 pandemic. It can also be stated that citizens of the Czech Republic are satisfied with the work of a nurse in their general practitioner’s office, and only a small part (5.4%) of them also have a negative opinion. Citizens perceive team practices positively, although (56.9%) prefer that they are always treated only by“their” general practitioner, which can be ensured within the framework of an ordering system. There are still significant reserves in the Czech Republic in the area of preventive care and only about 50% of citizens actively participate in it. The combination of VPL activities and citizens’ own motivation to improve their health is proving to be strong in the future. 80% of respondents rate prevention as important for improving their health and 75.4% of respondents would respect advice on lifestyle changes from a VPL or a specialist doctor as part of preventive care. Just under 1/3 (30.8%) of citizens believe that they live a healthy lifestyle, almost ½ (48.0%) of citizens believe that they live a healthy lifestyle occasionally. Citizens believe that the greatest risk that threatens them is lack of exercise (27.0%), another 23.7% of respondents identified poor nutrition as the greatest risk, 20.0% of citizens consider stress at work to be the greatest risk, and 19.8% lack of sleep. According to the respondents, the least risk is stress at home (indicated by 9.5% of respondents). The results will be used within the framework of the planned changes in preventive care for primary health care in the Czech Republic.
INTRODUCTION: Chitinase-3-like protein 1 (CHI3L1) is a glycoprotein implicated in various neurological conditions. It is associated with neuroinflammation and tissue remodeling. The study aimed to validate the reference interval (RI) of serum (S) CHI3L1 in a control group, to correlate S CHI3L1 values with other biomarkers of neurodegenerative damage, and to estimate the diagnostic accuracy of S CHI3L1. METHODS: Samples from 108 healthy volunteers were used to estimate the S CHI3L1 RI. For the comparison, we used cerebrospinal fluid (CSF) and serum (S) samples from 121 patients with cognitive disorders, and cognitive deterioration was assessed using the Mini-Mental State Examination (MMSE). ELISA assays were used to determine the S CHI3L1, CSF, and S neurofilament light chain (NfL) levels; CSF and plasma β-amyloid peptide42; CSF and plasma β-amyloid peptide40; CSF total tau protein; CSF phosphorylated tau protein; and CSF alpha-synuclein. RESULTS: The estimated RI of S CHI3L1 was 14.44 to 63.11 μg/L. The cut-off value of S CHI3L1 was 34.37 μg/L. ROC analysis showed that S CHI3L1 has 81.4% sensitivity and 76.9% specificity. We found a moderate Spearman's rank correlation coefficient between the S CHI3L1 and age (rS = 0.486; p < 0.001) and between S CHI3L1 and S NfL (rS = 0.489; p < 0.001) in all groups. The Kruskal-Wallis test showed a significant overall difference in S CHI3L1 among diagnostic groups (p = 0.013). S CHI3L1 and CSF NfL had statistically significant effects on MMSE values (multiple R2 was 0.431). CONCLUSIONS: Our results suggest that S CHI3L1 reflects the severity of cognitive deficits assessed by MMSE. It can be used as a supportive biomarker in neurodegenerative diseases.
- MeSH
- alpha-Synuclein cerebrospinal fluid blood MeSH
- Amyloid beta-Peptides blood cerebrospinal fluid MeSH
- Biomarkers blood cerebrospinal fluid MeSH
- Adult MeSH
- Cognitive Dysfunction * blood cerebrospinal fluid diagnosis MeSH
- Middle Aged MeSH
- Humans MeSH
- Neurofilament Proteins cerebrospinal fluid blood MeSH
- Movement Disorders * blood cerebrospinal fluid diagnosis MeSH
- Chitinase-3-Like Protein 1 * blood cerebrospinal fluid MeSH
- tau Proteins cerebrospinal fluid blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
BACKGROUND: The role of primary healthcare (PHC) during a pandemic varies across European countries. The coronavirus disease 2019 (COVID-19) pandemic has altered the working practices of family medicine doctors and impacted the resilience of healthcare systems. OBJECTIVES: This study aimed to examine European healthcare system responses to the pandemic, focusing on rural and urban differences. MATERIAL AND METHODS: This cross-sectional, mixed-methods study used a semi-structured online questionnaire with 68 questions, including 21 free-text comments. Data were collected from May 2020 to January 2021. Key informants from 16 European Rural and Isolated Practitioners Association (EURIPA) member countries distributed questionnaires to 406 PHC doctors. Data were analyzed using descriptive statistics and nonparametric tests (χ2, Kruskal-Wallis, Mann-Whitney U) with a significance threshold of 0.05. RESULTS: A statistically significant difference was found between rural (36.4%, 55/151), semirural (19.4%, 24/124) and urban populations (29.8%, 39/131) regarding medicine shortages (χ2 = 9.91, degrees of freedom (df) = 4, p = 0.042). The semirural setting showed a statistically significant difference from the other settings (p = 0.004 in post hoc χ2 test). Significant differences were found between countries in resilience features including, effectiveness of triage, adapting to the rapidly changing requirements, government help, existence of a community resilience group, improved interprofessional collaboration, medicine shortage, and general practitioners (GPs) involvement in palliative care. CONCLUSIONS: Medicine shortage was more prevalent in rural and urban areas compared to semirural areas. Differences were observed between countries in their responses to the pandemic, particularly in adapting to the rapidly changing requirements, effectiveness of triage, government help, and the existence of a community resilience group. These differences were confirmed with qualitative analysis. The results emphasize the need for tailored approaches considering diverse contexts in shaping effective healthcare system resilience.
- MeSH
- COVID-19 * epidemiology MeSH
- Humans MeSH
- Pandemics MeSH
- Primary Health Care * organization & administration MeSH
- Cross-Sectional Studies MeSH
- Surveys and Questionnaires MeSH
- SARS-CoV-2 MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Europe MeSH
BACKGROUND: Type 2 diabetes and prediabetes represent significant global health challenges, with physical activity (PA) being essential for disease management and prevention. Despite the well-documented benefits, many individuals with (pre)diabetes remain insufficiently active. General practitioners (GP) provide an accessible platform for delivering interventions; however, integrating PA interventions into routine care is hindered by resource constraints. OBJECTIVES: The ENERGISED trial aims to address these barriers through an innovative GP-initiated mHealth intervention combining wearable technology and just-in-time adaptive interventions. METHODS: The ENERGISED trial is a pragmatic, 12-month, multicentre, randomised controlled trial, assessing a GP-initiated mHealth intervention to increase PA and reduce sedentary behaviour in patients with type 2 diabetes and prediabetes. The primary outcome is daily step count, assessed via wrist-worn accelerometry. The primary analysis follows the intention-to-treat principle, using mixed models for repeated measures. Missing data will be handled under the missing-at-random assumption, with sensitivity analyses exploring robustness through reference-based multiple imputation. The trial incorporates the estimand framework to provide transparent and structured treatment effect estimation. DISCUSSION: This statistical analysis plan outlines a robust approach to addressing participant non-adherence, protocol violations, and missing data. By adopting the estimand framework and pre-specified sensitivity analyses, the plan ensures methodological rigour while enhancing the interpretability and applicability of results. CONCLUSIONS: The ENERGISED trial leverages innovative mHealth strategies within primary care to promote PA in individuals with (pre)diabetes. The pre-specified statistical framework provides a comprehensive guide for analysing trial data and contributes to advancing best practices in behavioural intervention trials for public health. TRIAL REGISTRATION: ClinicalTrials.gov NCT05351359 . Registered on April 28, 2022.
- MeSH
- Accelerometry MeSH
- Exercise * MeSH
- Diabetes Mellitus, Type 2 * therapy psychology diagnosis MeSH
- Fitness Trackers MeSH
- Humans MeSH
- Multicenter Studies as Topic MeSH
- Wearable Electronic Devices MeSH
- Pragmatic Clinical Trials as Topic MeSH
- General Practice * methods MeSH
- Prediabetic State * therapy psychology diagnosis MeSH
- Sedentary Behavior * MeSH
- Telemedicine * statistics & numerical data MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial Protocol MeSH
Za poslední dobu pozorujeme nárůst potřeby dětské psychiatrické péče, které je nedostatek, a proto velká část péče o dětské psychiatrické pacienty spadá do rukou pediatrů a praktických lékařů. V dnešní době tvoří nemalou část dětských psychiatrických pacientů i pacienti s poruchou příjmu potravy, jejich léčba a péče je většinou dlouhodobá, složitá a často relabující. Cestou kazuistiky bychom rádi objasnili péči o adolescentní pacienty s poruchou příjmu potravy v dětské psychiatrické ambulanci a na akutním lůžku dětské psychiatrie.
In recent times, we have seen an increase in the need for child psychiatric care, which is in short supply and therefore much of the care for child psychiatric patients falls to paediatricians and GPs. Nowadays, patients with eating disorder form a significant number of child psychiatric patients and their treatment and care is usually long-term, difficult and often relapsing. The task of this case report is to clarify the care of eating disorder in the child psychiatric outpatient clinic and in the psychiatric ward for children.
- MeSH
- Amenorrhea diagnosis etiology MeSH
- Weight Loss MeSH
- Hospitalization MeSH
- Humans MeSH
- Disease Management MeSH
- Anorexia Nervosa * diagnosis epidemiology psychology therapy MeSH
- Adolescent MeSH
- Feeding and Eating Disorders diagnosis epidemiology psychology therapy MeSH
- Check Tag
- Humans MeSH
- Adolescent MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
Depresivní a úzkostné poruchy představují významnou zátěž pro primární péči, přičemž poptávka po účinné a dobře tolerované léčbě stále roste. Souhrnný článek shrnuje současné poznatky o trazodonu - multifunkčním antidepresivu ze skupiny SARI, které kombinuje inhibici zpětného vychytávání serotoninu s antagonismem receptoru 5 HT2A. Přehled se zaměřuje na farmakodynamiku a farmakokinetiku léčiva, jeho antidepresivní, anxiolytické a sedativní vlastnosti i potenciální neuroprotektivní účinky. Klinická data dokládají srovnatelnou účinnost s SSRI/SNRI v léčbě velké depresivní poruchy a prokazují přínos u generalizované úzkostné poruchy, insomnie a chronické neuropatické bolesti. Nízké dávky (25-100 mg) se využívají ke zlepšení spánku, zatímco antidepresivní účinek vyžaduje titraci na 150-300 mg denně. Díky relativně příznivému profilu sexuálních nežádoucích účinků a nízké anticholinergní aktivitě je trazodon vhodný i pro starší polymorbidní pacienty. Článek diskutuje praktické aspekty preskripce v ordinaci praktického lékaře, možnosti kombinace s dalšími psychofarmaky a upozorňuje na klíčová bezpečnostní rizika, zejména ortostatickou hypotenzi, prodloužení QT intervalu a vzácný priapismus. Správná volba dávky, postupná titrace a edukace pacienta jsou nezbytné pro maximalizaci terapeutického přínosu a minimalizaci rizik této léčby.
Depressive and anxiety disorders represent a significant burden on primary care, and demand for effective and well-tolerated treatments continues to grow. This article summarises current knowledge of trazodone, a multifunctional antidepressant from the SARI group that combines serotonin reuptake inhibition with HT2A receptor 5 antagonism. This review focuses on the pharmacodynamics and pharmacokinetics of the drug, its antidepressant, anxiolytic, and sedative properties as well as its potential neuroprotective effects. Clinical data demonstrate comparable efficacy to SSRI/SNRIs in the treatment of major depressive disorder and demonstrate benefit in generalized anxiety disorder, insomnia, and chronic neuropathic pain. Low doses (25-100 mg) are used to improve sleep, while the antidepressant effect requires titration to 150-300 mg daily. The relatively favourable sexual side effect profile and low anticholinergic activity make trazodone suitable for elderly polymorbid patients. The article discusses the practicalities of prescribing in the general practitioner's office and options for combination with other psychopharmaceuticals. It also highlights key safety risks, particularly orthostatic hypotension, QT interval prolongation, and rare priapism. Proper dose selection, gradual titration, and patient education are essential to maximize the therapeutic benefit and minimize the risks of this treatment.
PI3K signaling pathway is crucial for a plethora of cellular processes and is extensively linked with tumorigenesis and chemo-/radioresistance. Although a number of small molecule inhibitors have been synthesized to control PI3K-mediated signaling, only a limited clinical success has been reached. Thus, the search for novel promising candidates is still ongoing. Herein, we present a novel series of N-(5-(2-morpholino-4-oxo-3,4-dihydroquinazolin-8-yl)pyridin-2-yl)acylamides designed to simultaneously inhibit PI3K and DNA-PK activity. Compared to a commercial DNA-PK/PI3K inhibitor AZD7648, synthesized compounds generally exhibited markedly lower baseline cytotoxicity in all tested cell lines (MC38, B16F10, 4T1, CT26 and HEK-239). Through an array of biological experiments, we selected two most promising compounds, 2 and 6. While in cell-free conditions, 6 acted as a very efficient pan-PI3K and DNA-PK inhibitor, in physiological conditions, 2 performed better and acted as a potent chemosensitizer able to increase the amount of DNA double strand breaks induced by doxorubicin. This was plausibly due to its improved ability to accumulate in nuclei as evidenced by confocal analyses. Importantly, using P-gp overexpressing CT26 cells, we found that 2 is an efficient inhibitor of multidrug resistance (MDR) able to down-regulate expression of mRNA encoding MDR-driving proteins ABCB1A, ABCB1B and ABCC1. We also demonstrate that 2 can be simply loaded into lipid nanoparticles that retain its chemosensitizing properties. Taken together, the presented study provides a solid basis for a subsequent rational structure optimization towards new generation of multitarget inhibitors able to control crucial signaling pathways involved in tumorigenesis and drug resistance.
- MeSH
- Drug Resistance, Neoplasm * drug effects MeSH
- Phosphatidylinositol 3-Kinases metabolism MeSH
- Phosphoinositide-3 Kinase Inhibitors * pharmacology MeSH
- Protein Kinase Inhibitors * pharmacology chemistry chemical synthesis MeSH
- Humans MeSH
- Drug Resistance, Multiple * drug effects MeSH
- Molecular Structure MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 * antagonists & inhibitors metabolism MeSH
- Cell Proliferation drug effects MeSH
- DNA-Activated Protein Kinase * antagonists & inhibitors metabolism MeSH
- Antineoplastic Agents * pharmacology chemistry chemical synthesis MeSH
- Drug Screening Assays, Antitumor MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Lung ultrasonography (LUS) is a point-of-care imaging modality with growing potential in primary care. OBJECTIVES: While its use is well established in hospital settings, data on its accuracy when performed by general practitioners (GPs) remain limited. This study aimed to assess the diagnostic accuracy of LUS conducted by GPs following structured training. METHODS: We recruited 17 GPs from various regions of the Czech Republic. They completed a two-day educational course focused on LUS. Patients with current dyspnoea (NYHA II-IV) or a history of dyspnoea within the last four weeks were included and underwent LUS to assess the presence of pleural effusion and interstitial syndrome. An independent expert sonographer, blinded to clinical data, evaluated recorded LUS video loops as the reference standard. LUS findings were categorized into A profile (presence of A lines and intact lung sliding, indicating normal aeration), B profile (three or more B lines per intercostal space in at least two intercostal spaces per hemithorax, suggesting interstitial syndrome), pulmonary consolidation and pleural effusion. RESULTS: A total of 128 patients were enrolled in the study. A total of 768 thoracic segments were examined. A profile was identified in 642 (83.6%) segments, B profile in 108 (14.1%), pulmonary consolidation in 8 (1.0%), and pleural effusion in 12 (1.6%). For the identification of A profile, the sensitivity was 97.51% (95% CI 95.98-98.57), and the specificity was 88.10% (95% CI 81,13-93,18); for B profile, the sensitivity was 87.04% (95% CI 79,21-92,73), and the specificity was 97.73% (95% CI96,28-98,72); for pulmonary consolidation, the sensitivity was 100.0% (95% CI 63,06-100,00), and the specificity was 100.0% (95% CI 99,52-100,0); for pleural effusion, the sensitivity was 83.33% (95% CI 51,59-97,91), and the specificity was 99.87% (95% CI 99,27-100,00). CONCLUSION: Our findings provide important preliminary data, demonstrating that GPs can perform LUS accurately after a structured training program. THE TRIAL REGISTRATION IDENTIFIER: is NCT04905719.
- MeSH
- Adult MeSH
- Dyspnea diagnostic imaging MeSH
- Lung Diseases, Interstitial diagnostic imaging MeSH
- Clinical Competence MeSH
- Middle Aged MeSH
- Humans MeSH
- Pleural Effusion diagnostic imaging MeSH
- Lung * diagnostic imaging MeSH
- Lung Diseases * diagnostic imaging MeSH
- General Practitioners * education MeSH
- Primary Health Care MeSH
- Cross-Sectional Studies MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Ultrasonography MeSH
- Point-of-Care Systems * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Geographicals
- Czech Republic MeSH
